Goat Anti-Human IgG Fab Antibody (HRP) (CAT#: MOB-0361MC)

Gehrlein, Alexandra, et al. "Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct." Nature communications 14.1 (2023): 2057. https://doi.org/s41467-023-37632-4

This study investigates the development of a therapeutic strategy targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase (GCase) deficiency, which is linked to Gaucher's disease and Parkinson's disease. Researchers engineered a brain-penetrant enzyme construct, GCase-BS, combining β-glucocerebrosidase with a transferrin receptor-binding moiety to facilitate its passage across the blood-brain barrier. The GCase-BS construct showed improved lysosomal uptake and function, effectively reducing pathological lipid accumulations in cellular and mouse models.
Creative Biolabs provided the HRP-conjugated pAb anti-hFab(CH1) antibody (Cat# MOB-0361MC) used in this study. This antibody was essential for measuring IgG levels of the GCase-BS molecules after incubation in mouse plasma. By enabling accurate detection and quantification of IgG levels, the antibody from Creative Biolabs supported the researchers in assessing both the enzymatic activity of GCase and the stability of the GCase-BS constructs, thereby contributing to the evaluation of their therapeutic potential.

Roubidoux, Ericka Kirkpatrick, et al. "Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2." Scientific Reports 13.1 (2023): 17820. https://doi.org/s41598-023-44989-5

This study investigates the utility of nasal swabs for assessing mucosal immune responses to SARS-CoV-2. The researchers developed a novel methodology to measure cytokine and antibody responses in the nasal epithelium using nasopharyngeal swabs collected before and after SARS-CoV-2 infection or vaccination. They compared these mucosal responses to systemic responses, finding distinct cytokine profiles in nasal versus plasma samples. The study also examined the kinetics of nasal IgA and IgG antibodies post-infection and vaccination, highlighting the importance of mucosal immunity in respiratory infections.
Creative Biolabs provided the HRP-conjugated anti-human IgG antibody (Cat# MOB-0361MC) used in the total IgG ELISA assays. This antibody was crucial for detecting and quantifying IgG levels in nasal swab samples, allowing the researchers to accurately measure SARS-CoV-2 specific IgG responses. By enabling precise quantification of IgG, the antibody from Creative Biolabs supported the study's exploration of the dynamics of mucosal antibody responses, contributing to a better understanding of immunity at the nasal epithelium.